Lipoprotein apheresis in the management of familial hypercholesterolaemia: Historical perspective and recent advances

Current Atherosclerosis Reports

Volumn 17, Issue 1, 2015, Pages

  Stefanutti, Claudia ^a,b   Thompson, Gilbert R ^c  

^a POLICLINICO UMBERTO I   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Cholesterol; Evolocumab; Ezetimibe; LDL receptor; Lomitapide; Low density lipoprotein; Mipomersen; Plasmapheresis; Statin

Indexed keywords

EID: 84927764140     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-014-0465-6     Document Type: Review

References (87)

1. de Gennes JL, Touraine R, Maunand B, Truffert J, Laudat P. Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis an heroic treatment. Bull Mem Soc Med Hôp Paris. 1967;118:1377–402.
2. Turnberg LA, Mahoney MP, Gleeson MH, Freeman CB, Gowenlock AH. Plasmapheresis and plasma exchange in the treatment of hyperlipaemia and xanthomatous neuropathy in patients with primary biliary cirrhosis. Gut. 1972;13:976–81.
3. Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet. 1975;l:l208–11.
4. Berger GM, Miller JL, Bonnici F, Joffe HS, Dubovsky DW. Continuous flow plasma exchange in the treatment of homozygous familial hypercholesterolemia. Am J Med. 1978;65:243–51.
5. King ME, Breslow JL, Lees RS. Plasma-exchange therapy of homozygous familial hypercholesterolemia. N Engl J Med. 1980;302:1457–9.
6. Lupien PJ, Moorjani S, Awad J. A new approach to the management of familial hypercholesterolaemia: removal of plasma-cholesterol based on the principle of affinity chromatography. Lancet. 1976;1:1261–5.
7. Stoffel W, Borberg H, Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet. 1981;2:1005–7.
8. Thompson GR. Lipoprotein apheresis. Curr Opin Lipidol. 2010;21:487–91.
9. Richter WO, Jacob BG, Ritter MM, Sühler K, Vierneisel K, Schwandt P. Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism. 1993;42:888–94.
10. Agishi T, Kaneko I, Hasuo Y, et al. Double filtration plasmapheresis. Trans Am Soc Artif Intern Organs. 1980;26:406–11.
11. Klingel R, Mausfeld P, Fassbender C, Goehlen B. Lipidfiltration—safe and effective methodology to perform lipid-apheresis. Transfus Apher Sci. 2004;30:245–54.
12. Yokoyama S, Hayashi R, Satani M, Yamamoto A. Selective removal of low density lipoprotein by plasma pheresis in familial hypercholesterolemia. Arteriosclerosis. 1985;5:613–22.
13. Mabuchi H, Michishita I, Takeda M, et al. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). Atherosclerosis. 1989;68:19–26.
14. Gordon BR, Kelsey SF, Bilheimer DW, et al. Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Am J Cardiol. 1992;70:1010–6.
15. Gordon BR, Kelsey SF, Dau PC, for the Liposorber Study Group, et al. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Am J Cardiol. 1998;81:407–11.
16. Eisenhauer T, Armstrong VW, Wieland H, Fuchs C, Scheler F, Seidel D. Selective removal of low density lipoproteins (LDL) by precipitation at low pH; first clinical application of the HELP system. Klin Wochenschr. 1987;65:161–8.
17. Armstrong VW, Windisch M, Wieland H, et al. Selective continuous extracorporeal elimination of low-density lipoproteins with heparin at acidic pH. Trans Am Soc Artif Intern Organs. 1983;29:323–8.
18. Armstrong VW, Schuff-Werner P, Eisenhauer T, Helmhold M, Stix M, Seidel D. Heparin extracorporeal LDL precipitation (HELP): an effective apheresis procedure for lowering Lp(a) levels. Chem Phys Lipids. 1994;67–68:315–21.
19. Lane D, McConathy WJ, Laughlin LO, et al. Selective removal of plasma low density lipoprotein with the HELP system: biweekly versus weekly therapy. Atherosclerosis. 1995;114:203–11.
20. Bosch T, Schmidt B, Blumenstein M, Gurland HJ. Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artif Organs. 1993;17:640–52.
21. Julius U, Parhofer KG, Heibges A, Kurz S, Klingel R, Geiss HC. Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis—comparison of performance characteristics with DALI and Lipidfiltration. J Clin Apher. 2007;22:215–23.
22. Thompson GR, HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008;198:247–55.
23. Richter WO, Donner MG, Schwandt P. Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation. Ther Apher. 1999;3:203–8.
24. Watts GF, Hamilton SJ. LDL apheresis for familial hypercholesterolemia: value, indications and demand. Clin Lipidol. 2009;4:129–31.
25. Stefanutti C, Lanti A, Di Giacomo S, et al. Therapeutic apheresis in low weight patients: technical feasibility, tolerance, compliance, and risks. Transfus Apher Sci. 2004;31:3–10.
26. Sinzingera H, Bednar J, Granegger S, Blazek I, Peskar BA. LDL-apheresis and concomitant ACE-inhibitor therapy. Atherosclerosis. 1994;105:115–6.
27. Cashin-Hemphill L, Noone M, Abbott JF, Waksmonski CA, Lees RS. Low-density lipoprotein apheresis therapy during pregnancy. Am J Cardiol. 2000;86:1160. A10.
28. Goldstein JL, MS B. The LDL receptor defect in familial hypercholesterolemia. Implications for pathogenesis and therapy. Med Clin N Am. 1982;66:335–62.
29. van der Westhuyzen DR, Coetzee GA, Demasius IP, Harley EH, Gevers W, Baker SG, et al. Low density lipoprotein receptor mutations in South African homozygous familial hypercholesterolemic patients. Arteriosclerosis. 1984;4:238–47.
30. Gautschi M, Pavlovic M, Nuoffer JM. Fatal myocardial infarction at 4.5 years in a case of homozygous familial hypercholesterolaemia. JIMD Rep. 2012;2:45–50. Describes seven cases of extremely premature mortality in FH homozygotes.
31. Keller C. LDL-Apheresis in homozygous LDL-receptor-defective familial hypercholesterolemia: the Munich experience. Atheroscler Suppl. 2009;10:21–6.
32. Mabuchi H, Nohara A, Noguchi T, et al. Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan. Atherosclerosis. 2011;214:404–7. This paper describes the clinical and molecular characteristics of 25 FH homozygotes in the Hokuriko district of Japan, 3 of whom lived past the age of 50.
33. Graesdal A, Bogsrud MP, Holven KB, et al. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J Clin Lipidol. 2012;6:331–9. Description of progression of cardiovascular disease in FH homozygotes in Norway despite rigorous lipoprotein apheresis and drug therapy.
34. Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011;124:2202–7. Comparison of serum cholesterol levels and mortality in FH homozygotes in South Africa in the pre- and post-statin eras.
35. Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated by plasma exchange. Br Med J. 1989;291:1671–3.
36. Thompson GR, Maher VM, Matthews S, et al. Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 1995;345:811–6.
37. Kroon AA, Aengevaeren WR, van der Werf T, LDL-Apheresis Atherosclerosis Regression Study (LAARS), et al. Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 1996;93:1826–35.
38. Nishimura S, Sekiguchi M, Kano T, et al. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis. 1999;144:409–17.
39. Mabuchi H, Koizumi J, Shimizu M, Hokuriku-FH-LDLApheresis Study Group, et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am J Cardiol. 1998;82:1489–95.
40. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.
41. Kavey R-E W, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients. A scientific statement from the american heart association expert panel on population and prevention science; the councils on cardiovascular disease in the young, epidemiology and prevention, nutrition, physical activity and metabolism, high blood pressure research, cardiovascular nursing, and the kidney in heart disease; and the interdisciplinary working group on quality of care and outcomes research. Circulation. 2006;114:2710–38.
42. Sczepiorkowski ZM, Bandarenko M, Kim HC, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the apheresis applications committee of the American society for apheresis. J Clin Apher. 2007;22:106–75.
43. Ito MK, McGowan MP, Moriarty PM, National Lipid Association Expert Panel on Familial Hypercholesterolemia. Management of familial hypercholesterolemias in adult patients: recommendations from the national lipid association expert panel on familial hypercholesterolemia. J Clin LipidoI. 2011;5:S38–45. US guidelines on therapeutic management of FH.
44. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J. 1998;19:1434–1503.
45. Gemeinsamer-Bundesausschuss. Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Richtlinie Methoden vertragsärztliche Versorgung: Apherese bei isolierter Lp(a)-Erhöhung für Studienteilnehmer. BAnz 2009;128:3005.
46. Civiera F, for International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004;173:55–68.
47. Stefanutti C. The 2009 2nd Italian consensus conference on LDL-apheresis. Nutr Metab Cardiovasc Dis. 2010;20:761–2.
48. Harada-Shiba M, Arai H, Oikawa S, et al. Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb. 2012;19:1043–60. Japanese guidelines on the therapeutic management of FH.
49. Palcoux J-B, Atassi-Dumont M, Lefevre P, et al. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Ther Apher Dial. 2008;12:195–201.
50. Hudgins L, Kleimann B, Scheuer A, White S, Gordon BR. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am J Cardiol. 2008;102:1199–204.
51. Kolansky DM, Cuchel M, Clark BJ, et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol. 2008;102:1438–43.
52. Stefanutti C, Vivenzio A, Giacomo S, et al. Aorta and coronary angiographic follow-up of children with severe hypercholesterolemia treated with low-density lipoprotein apheresis. Transfusion. 2009;49:1461–70.
53. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus Statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478–90. Latest European guidelines on the therapeutic management of FH.
54. Gagné C, Gaudet D, Bruckert E, et al. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105:2469–75.
55. Raal FJ, Pilcher GJ, Illingworth DR, et al. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis. 1997;135249–56.
56. Marais AD, Blom DJ, Firth JC. Statins in homozygous familial hypercholesterolemia. Curr Atheroscler Rep. 2002;4:19–25.
57. Naoumova RP, Thompson GR, Soutar AK. Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol. 2004;15:413–22.
58. Gordon BR. Incorporation of low-density lipoprotein apheresis into the treatment program of patients with severe hypercholesterolemia. Curr Atheroscler Rep. 2000;2:308–13.
59. Kawaguchi A, Miyatake K, Yutani C, et al. Characteristic cardiovascular manifestation in homozygous and heterozygous familial hypercholesterolemia. Am Heart J. 1999;137:410–8.
60. Awan Z, Alrasadi K, Francis GA, et al. Vascular calcifications in homozygote familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2008;28:777–85.
61. Bilheimer DW, Goldstein JL, Grundy SM, Starzl TE, Brown MS. Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia. N Engl J Med. 1984;311:1658–64.
62. Revell SP, Noble-Jamieson G, Johnston P, Rasmussen A, Jamieson N, Barnes ND. Liver transplantation for homozygous familial hypercholesterolaemia. Arch Dis Child. 1995;73:456–8.
63. Kakaei F, Nikeghbalian S, Kazemi K, et al. Liver transplantation for homozygous familial hypercholesterolemia: two case reports. Transplant Proc. 2009;41:2939–41.
64. Grossman M, Raper SE, Kozarsky K, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet. 1994;6:335–41.
65. Raper SE, Grossman M, Rader DJ, et al. Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia. Ann Surg. 1996;223:116–26.
66. Rader DJ. Gene therapy for familial hypercholesterolemia. Nutr Metab Cardiovasc Dis. 2001;11 Suppl 5:40–4.
67. Van Craeyveld E, Jacobs F, Gordts SC, De Geest B. Gene therapy for familial hypercholesterolemia. Curr Pharm Des. 2011;17:2575–91. Review on experimental LDLr gene transfer studies demonstrating regression of atherosclerosis in experimental models.
68. Thompson GR. The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. Atheroscler Suppl. 2013;14:67–70. Latest evidence-based review on lipoprotein apheresis.
69. Stefanutti C, Julius U. Lipoprotein apheresis: state of the art and novelties. Atheroscler Suppl. 2013;14:19–27. Review and update on recent indications of lipoprotein apheresis and prospects of novel lipid-altering drugs for the treatment of severe dyslipidaemia.
70. Yamamoto A, Harada-Shiba M, et al. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy. Atherosclerosis. 2006;186:126–31.
71. Bays H, Stein EA. Pharmacotherapy for dyslipidaemia–current therapies and future agents. Expert Opin Pharmacother. 2003;4:1901–38.
72. Stefanutti C, Morozzi C, Di Giacomo S. New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia. Curr Med Chem. 2012;19:4861–8. Review and update of novel lipid-altering drugs for treatment of lipid metabolism disorders.
73. Bell DA, Hooper AJ, Watts GF, Burnett JR. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. Vasc Health Risk Manag. 2012;8:651–9. Recent review on mipomersen for the treatment of severe FH.
74. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356:148–56.
75. Hooper AJ, Burnett JR. Anti-PCSK9 therapies for the treatment of hypercholesterolemia. Expert Opin Biol Ther. 2013;13:429–35. The review summarizes the latest findings in clinical trials of PCSK9 inhibitors, including antibodies, gene silencing and small peptides.
76. Visser ME, Kastelein JJ, Stroes ES. Apolipoprotein B synthesis inhibition: results from clinical trials. Curr Opin Lipidol. 2010;21:319–23.
77. U.S. Food and Drug Administration. FDA approves new orphan drug for rare cholesterol disorder. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333285.htm.
78. U.S. Food and Drug Administration. FDA approves new orphan drug Kynamro to treat inherited cholesterol disorder. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm337195.htm.
79. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998–1006.
80. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40–6. Phase 3 multicentre study on treatment of homozygous FH individuals with Lomitapide.
81. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013;128:2113–20. First clinical trial of PCSK9 inhibitor AMG 145 in homozygous FH subjects.
82. European Medicines Agency, European public assessment report (EPAR) EMA/519736/2013 EMEA/H/C/002578, pp 1–3. 18. Statement of approval of Lojuxta (lomitapide) as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without LDL-apheresis, issued by the European Commission.
83. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367:1891–900. Randomized clinical trial involving patients with primary hypercholesterolemia, adding a PCSK9 inhibitor to either 10 mg of atorvastatin or 80 mg of atorvastatin.
84. Nachimuthu S, Raggi P. Novel agents to manage dyslipidemias and impact atherosclerosis. Cardiovasc Hematol Disord Drug Targets. 2006;6:209–17.
85. Vuorio A, Tikkanen MJ, Kovanen PT. Inhibition of hepatic microsomal triglyceride transfer protein—a novel therapeutic option for treatment of homozygous familial hypercholesterolemia. Vasc Health Risk Manag. 2014;10:263–70. Review on lomitapide as novel therapeutic option for treatment of HoFH subjects.
86. Page MM, Bell DA, Hooper AJ, Watts GF, Burnett JR. Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children. Best Pract Res Clin Endocrinol Metab. 2014;28:387–403. This review describes the rationale and role of lipoprotein apheresis in the treatment of severe FH and outlines the recent advances in pharmacotherapies for this condition.
87. Schwartz J, Winters JL, Padmanabhan A. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013;28:145–284. Latest guidelines on therapeutic apheresis of the American Society of Apheresis.